| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kevin D Freeman is Director at GALT. Kevin D Freeman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $185K at current prices.
Our model assigns Kevin D Freeman a middling insider score of 57/100, based on 17 past trades. Over a 12-month horizon, 43.8% of those trades were profitable, with an average 12-month return of +1.5%.
Net of sales, the GALT filings show accumulation of 119,309 shares.
Kevin D Freeman has 40 Form 4 filings on record from March 2015 to January 2026, all as Director at Galectin Therapeutics (GALT), 2015–2026.
The 47 reported transactions were 32 open-market purchases, 11 option or other derivative awards, 2 stock awards and 1 inheritance, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 28 purchases worth about $300K and no sales.
The largest open-market purchase was 9,136 shares of GALT at an average $4.28 on May 31, 2019, about $39K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | GALT Galectin Therapeutics Inc | Director | Buy10b5-1 | 5,500 | $3.55 | $19,514.00 | +11.1% | -28.3% | - | |
| Jul 17, 2025 | GALT Galectin Therapeutics Inc | Director | Buy | 5,000 | $2.90 | $14,495.00 | +11.2% | +79.6% | +44.6% | |
| Dec 24, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 10,000 | $0.81 | $8,134.00 | +28.8% | +96.3% | +379.4% | |
| Oct 17, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 1,300 | $2.64 | $3,432.00 | +3.9% | -51.9% | +87.6% | |
| Oct 16, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 10,000 | $2.70 | $27,000.00 | +14.3% | -56.3% | +92.0% | |
| Jun 20, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 2,500 | $2.38 | $5,949.75 | +9.6% | +12.0% | 0.0% | |
| Apr 22, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 2,500 | $2.98 | $7,450.00 | +10.7% | -19.0% | -56.5% | |
| Oct 28, 2022 | GALT Galectin Therapeutics Inc | Director | Buy | 10,000 | $1.41 | $14,100.00 | +15.4% | -20.1% | +43.2% | |
| May 19, 2022 | GALT Galectin Therapeutics Inc | Director | Buy | 5,000 | $1.33 | $6,649.50 | +8.3% | +59.1% | +32.6% | |
| Apr 18, 2022 | GALT Galectin Therapeutics Inc | Director | Buy | 5,000 | $1.71 | $8,550.00 | +9.1% | -3.6% | +17.9% |